Medical News

RSS

New study refutes common assumptions about consent forms in clinical trials

Although informed consent is an ethical cornerstone in research with humans, some studies suggests that volunteers often do not understand key aspects of the research in which they participate. Recent efforts have been made to improve informed consent by simplifying the consent forms.

11 Aug 2010

PregLem announces exclusive in licensing agreement with Merck Serono for Bentamapimod

PregLem, the Swiss specialty biopharmaceutical company focused on women's reproductive medicine, announces a world-wide, exclusive in licensing agreement for Bentamapimod, a novel, orally active, Jun Kinase Inhibitor from Merck Serono for an undisclosed amount. PregLem will develop the compound for the prevention of post-surgical abdominal adhesions and endometriosis in patients with tubal ligation or comparable effective contraception.

11 Aug 2010

NextGen Healthcare receives ACCME accreditation

NextGen Healthcare Information Systems, Inc., a wholly owned subsidiary of Quality Systems, Inc. and leading provider of healthcare information systems and connectivity solutions, today announced that it has been surveyed by the Accreditation Council for Continuing Medical Education (ACCME) and awarded accreditation for two years as a provider of continuing medical education for physicians.

11 Aug 2010

Temperature increases could slow rice production, study says

A study published online Monday in Proceedings of the National Academy of Sciences found that anticipated temperature increases "could slow the growth of rice production unless farmers adapt by changing management practices and switch to more heat-tolerant varieties," Reuters reports (Fogarty, 8/10).

11 Aug 2010

Medicago USA awarded $21M to develop vaccine facility in Research Triangle Park

Medicago USA Inc., a wholly owned subsidiary of Medicago Inc., a clinical-stage biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that it has been awarded a $21 Million grant from the Defense Advanced Research Projects Agency, Broad Agency Announcement, Defense Sciences Research & Technology to demonstrate the scalable manufacturing of its plant-expressed VLP vaccines in the U.S.A. under a Technology Investment Agreement.

11 Aug 2010

San Antonio Community Hospital completes system-wide conversion to Masimo rainbow technology

San Antonio Community Hospital in Upland, California, and Masimo, the inventor of Masimo rainbow Pulse CO-Oximetry™, Masimo rainbow Acoustic Monitoring™, and Masimo SET® Measure-Through Motion and Low Perfusion pulse oximetry, today jointly announced the completion of San Antonio Community Hospital's system-wide conversion to Masimo rainbow technology.

11 Aug 2010

AACN endorses new clinical practice guidelines developed by Renal Physicians Association

The American Association of Critical-Care Nurses (AACN) recently endorsed the clinical practice guideline, "Shared Decision Making in the Appropriate Initiation of and Withdrawal from Dialysis," developed by Renal Physicians Association (RPA), Rockville, Md.

11 Aug 2010

New computerized approach for dental restoration procedures

Oral surgeons may one day have an easier, less costly approach to one important aspect of dental restoration, thanks to a newly patented process developed by researchers at Missouri University of Science and Technology (Missouri S&T).The process computerizes the method for creating a dental bar, also called an over-denture. For dental restoration procedures, the device is the bridge connecting dental implants to dentures.

11 Aug 2010

Silence Therapeutics receives patent for RNA silencing method

Silence Therapeutics plc announces the issuance of United States patent 7,772,203, titled "Methods and Compositions for Controlling Efficacy of RNA Silencing," by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of enhancing RNA silencing with a double stranded RNA interference (RNAi) agent. The patent's RNA silencing method claims include coverage for the administering of a pharmaceutical composition containing short interfering RNA (siRNA), micro RNA (miRNA), pre-miRNA or short hairpin (shRNA) molecules. Silence believes the proprietary structural modification techniques covered in this patent will play a key role in increasing the potential therapeutic efficacy of RNAi therapeutics.

11 Aug 2010

Methodist Healthcare System to implement TeleTracking Technologies' RadarFind RTLS

Citing superior accuracy and performance, the Methodist Healthcare System, San Antonio, TX, has selected TeleTracking Technologies' RadarFind real-time locating system to track thousands of assets, and eventually patients, across multiple facilities.

11 Aug 2010

ITI signs NPWT contract with MAGNET

Innovative Therapies Inc. announced today the signing of a negative pressure wound therapy contract with the Mid-Atlantic Group Network of Shared Services, encompassing both rental and sales of ITI's proprietary NPWT technology.

11 Aug 2010

Lutronic second-quarter revenues increase 15% to $11.5 million

Lutronic Corp commenced the month by announcing second-quarter financial results for the three month period, ending June 30, 2010.

11 Aug 2010

ACR announces revised classification criteria for rheumatoid arthritis

The American College of Rheumatology announced the release of revised classification criteria (created in collaboration with the European League Against Rheumatism) for rheumatoid arthritis, which will allow the study of treatments for RA at much earlier stages of the disease—before joint damage occurs—ultimately leading to better patient outcomes.

11 Aug 2010

Pakistan floods continue, news outlets look at U.S. response

As rains and flooding in Pakistan continue, "the U.S. is racing to provide basic human needs, like makeshift housing," the Christian Science Monitor reports in an article looking at how the U.S. disaster response is being shaped by "the global battle with militant Islam."

11 Aug 2010

Sanofi-aventis, Scripps Genomic Medicine collaborate to advance research in individualized medicine

Sanofi-aventis and Scripps Genomic Medicine, a division of Scripps Health, announced today a strategic alliance to advance research and development initiatives in the field of individualized medicine.

11 Aug 2010

GenSpera issued additional patent for G-202

GenSpera, Inc. announced that its patent application, entitled "Tissue Specific Prodrugs," has been issued by the United States Patent and Trademark Office as US Patent 7,767,648. The patent covers the method of use for G-202, GenSpera's lead oncology drug, which is currently in a Phase I clinical study treating cancer patients whose disease has progressed after other treatments.

11 Aug 2010

New optical imaging technique holds potential to improve angioplasty

A new optical imaging technique described in the journal Review of Scientific Instruments, which is published by the American Institute of Physics, holds the potential to greatly improve angioplasty, a surgery commonly performed to treat patients with a partially or completely blocked coronary artery that restricts blood flow to the heart.

11 Aug 2010

Premier international conference to highlight understanding of cancer disparities

This year, the American Association for Cancer Research will host its third conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved at the Loews Miami Beach Hotel in Miami, Fla.

11 Aug 2010

NKTreg white blood cells migrate into liver, suppress immune responses: Research

After a transplant - and to assure that the new organ is not rejected - patients are put on life-long therapy to suppress their immune system, which, nevertheless, needs to be left intact enough to be able to defend the body against all kinds of disease. A tricky balance as the many rejected organs attest. But a discovery by Maria Monteiro and Luis Graça, two Portuguese scientists, could change all this, at least for the liver.

11 Aug 2010

Tamir Biotechnology's three compounds effective show potential for yellow fever

Tamir Biotechnology, Inc.(formerly Alfacell Corporation) announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) confirmed that testing of three of our company's compounds showed in vitro results rarely seen before by the U.S. government for yellow fever.

11 Aug 2010